Zoetis (ZTS) looks undervalued: 17.3x forward P/E, $150 target with 25% upside, plus dividends/buybacks—see key risks and ...

Looking for the hottest name in health care? Right now it's not big pharma nor even a hot biotech firm making waves on Wall Street; it's newly minted animal health firm Zoetis. After shares of ...

Zoetis Inc. is no longer a 'Sell' after a 48% decline from its all-time high, with valuation multiples now more reasonable. Despite a wide economic moat and solid long-term growth prospects, Zoetis ...

One is a sector mainstay that has now raised its payout 17 years in a row. The other is a big player in the animal healthcare space. It's not too late to take advantage of either. While the ...